Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 04, 2023 06:45 ET
|
Cingulate Inc.
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04,...
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
December 01, 2022 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
November 30, 2022 15:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
November 14, 2022 06:45 ET
|
Cingulate Inc.
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety...
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
November 01, 2022 09:02 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Present at LD Micro Investor Conference
October 20, 2022 14:20 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 11, 2022 06:45 ET
|
Cingulate Inc.
$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage...